FindTrial
Sign In

Study of treatment outcomes in patients with non-uterine soft tissue sarcoma

Non Uterine Leiomyosarcoma: Real World Outcomes with Systemic Therapy from a Tertiary Cancer Centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106906
Enrollment
450
Registered
2026-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C45-C49- Malignant neoplasms of mesothelial and soft tissue

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Histologically, leiomyosarcoma 2. Referral to adult medical oncology Bone and Soft Tissue Cancer Outpatient Department and Gastrointestinal Unit Outpatient Department for chemotherapy opinion. 3. Time period: Patient diagnosed between January 2014 and December 2024. 4. Age more than 18 years. 5. Any ECOG performance status.

Exclusion criteria

Exclusion criteria: NONE

Design outcomes

Primary

MeasureTime frame
Overall Survival (OS) Timepoint: 3 years—

Secondary

MeasureTime frame
Progression-Free Survival (PFS)-3 years Disease-free survival (DFS) Adverse Events Lost to Follow-up Rate Timepoint: Progression-Free Survival (PFS)-3 years Disease-free survival (DFS) - 3 years—

Countries

India

Contacts

Public ContactDr Prabhat Bhargava

Tata Memorial Center , Mumbai

bhargava611@gmail.com7276174221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026